Skip to main content
. 2011 Jul 29;6(7):e22882. doi: 10.1371/journal.pone.0022882

Figure 3. ANGPT2 signaling in skeletal myoblasts.

Figure 3

A: Representative immunoblots and optical densities of total and phosphorylated AKT and ERK1/2 proteins in human skeletal myoblasts exposed for 15 min to increasing concentrations of ANGPT2. N = 4 per group. B: Representative immunoblots and optical densities of total and phosphorylated AKT and ERK1/2 proteins in human skeletal myoblasts exposed to 600 ng/ml ANGPT2 for increasing durations. N = 4 per group. C–D: Cytotoxicity and caspase 3/7 activity in human skeletal myoblasts maintained for 36 h in media containing 0%FBS (control) or 0%FBS + ANGPT2 in the presence of PD184352, (PD, ERK1/2 inhibitor), wortmannin, (WM, PI3 kinase inhibitor) and API2 (AKT inhibitor). *P<0.05 compared with control.

HHS Vulnerability Disclosure